Abstract
Outcomes following 50 mg <i>versus</i> 100 mg alemtuzumab in reduced‐intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
